Skip to main content
SpringerLink
Log in

The Mammalian Target of Rapamycin and Multiple Myeloma

  • Chapter
Book cover Myeloma Therapy

Part of the book series: Contemporary Hematology ((CH))

  • 513 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosup-pressant rapamycin in yeast. Science 1991; 253:905–9.

    Article  PubMed  CAS  Google Scholar 

  2. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT 1: A mammalian protein that binds to FKBP 12 in a rapamycin-dependent fashion and ishomologous to yeast TORs. Cell 1994; 78:35–43.

    Article  PubMed  CAS  Google Scholar 

  3. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by Gl-arrest-ing rapamycin-receptor complex. Nature 1994; 369:756–8.

    Article  PubMed  CAS  Google Scholar 

  4. Chiu MI, Katz H, Berlin V. RAPTl, a mammalian homolog of yeast Tor, interacts with the FKBPl2/rapamycin complex. Proc Natl Acad Sci USA 1994; 91:12574–8.

    Article  PubMed  CAS  Google Scholar 

  5. Groves MR, Hanlon N, Turowski P, Hemmings BA, Barford D. The structure of the protein phosphatase 2A PR65/A subunit reveals the conformation of its 15 tandemly repeated HEAT motifs. Cell 1999; 96:99–110.

    Article  PubMed  CAS  Google Scholar 

  6. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBPl2-rapamycin complex interacting with the binding domain of human FRAP. Science 1996; 273:239–42.

    Article  PubMed  CAS  Google Scholar 

  7. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110:177–89.

    Article  PubMed  CAS  Google Scholar 

  8. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110:163–75.

    Article  PubMed  CAS  Google Scholar 

  9. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122–8.

    Article  PubMed  CAS  Google Scholar 

  10. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15:807–26.

    Article  PubMed  CAS  Google Scholar 

  11. Abraham RT. Identification of TOR signaling complexes: More TORC for the cell growth engine. Cell 2002; 111:9–12.

    Article  PubMed  CAS  Google Scholar 

  12. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471–84.

    Article  PubMed  CAS  Google Scholar 

  13. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003; 17:1829–34.

    Article  PubMed  CAS  Google Scholar 

  14. Inoki K, Li Y, Zhu T, W u J Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4:648–57.

    Article  PubMed  CAS  Google Scholar 

  15. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002; 10:151–62.

    Article  PubMed  CAS  Google Scholar 

  16. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase activating protein complex toward. Rheb Curr Biol 2003; 13:1259–68.

    Article  CAS  Google Scholar 

  17. Hyun T, Yam A, Pece S, et al. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 2000; 96:3560–8.

    PubMed  CAS  Google Scholar 

  18. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL. Regulation of the TSC pathway by LKB 1: Evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 2004; 18:1533–8.

    Article  PubMed  CAS  Google Scholar 

  19. Nobukuni T, Joaquin M, Roccio M, et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 30H-kinase. Proc Natl Acad Sci USA 2005; 102:14238–43.

    Article  PubMed  CAS  Google Scholar 

  20. Hsu J, Shi Y, Krajewski S, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001; 98:2853–5.

    Article  PubMed  CAS  Google Scholar 

  21. Qiang YW, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: Downstream elements, functional correlates, and pathway cross-talk. Blood 2002; 99:4138–46.

    Article  PubMed  CAS  Google Scholar 

  22. Hsu JH, Shi Y, Frost P, et al. Interleukin-6 activates phosphoinositol-3 kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. Oncogene 2004; 23:3368–75.

    Article  PubMed  CAS  Google Scholar 

  23. Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem 2002; 277:15712–20.

    Article  PubMed  CAS  Google Scholar 

  24. Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996; 88:2699–706.

    PubMed  CAS  Google Scholar 

  25. Neri A, Murphy JP, Cro L, et al. Ras oncogene mutation in multiple myeloma. J Exp Med 1989; 170:1715–25.

    Article  PubMed  CAS  Google Scholar 

  26. Yoganathan N, Yee A, Zhang Z, et al. Integrin-linked kinase, a promIsmg cancer therapeutic target: Biochemical and biological properties. Pharmacol Ther 2002; 93:23342.

    Article  Google Scholar 

  27. Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002; 62:5027–34.

    PubMed  CAS  Google Scholar 

  28. Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK. Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res 2006; 30:262–5.

    Article  PubMed  CAS  Google Scholar 

  29. Bahlis NJ, Miao Y, Koc ON, Lee K, Boise LH, Gerson SL. N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. Leuk Lymphoma 2005; 46:899–908.

    Article  PubMed  CAS  Google Scholar 

  30. Dufner A, Andjelkovic M, Burgering BM, Hemmings BA, Thomas G. Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. Mol Cell Biol 1999; 19:4525–34.

    PubMed  CAS  Google Scholar 

  31. Brown EJ, Schreiber SL. A signaling pathway to translational control. Cell 1996; 86:51720.

    Google Scholar 

  32. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5TOP mRNA translation through inhibition of p70s6k. Embo J 1997; 16:3693–704.

    Article  PubMed  CAS  Google Scholar 

  33. Sachs AB. Cell cycle-dependent translation initiation: IRES elements prevail. Cell 2000; 101:243–5.

    Article  PubMed  CAS  Google Scholar 

  34. Vagner S, Galy B, Pyronnet S. Irresistible IRES. Attracting the translation machinery to internal ribosome entry sites. EMBO Rep 2001; 2:893–8.

    Article  PubMed  CAS  Google Scholar 

  35. Pestova TV, Kolupaeva VG, Lomakin IB, et al. Molecular mechanisms of translation initiation in eukaryotes. Proc Natl Acad Sci USA 2001; 98:7029–36.

    Article  PubMed  CAS  Google Scholar 

  36. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: Roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000; 60:6763–70.

    PubMed  CAS  Google Scholar 

  37. Hsu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003; 101:3126–35.

    Article  PubMed  Google Scholar 

  38. Yang YP, Liang ZQ, Gu ZL, Qin ZH. Molecular mechanism and regulation of autophagy. Acta Pharmacol Sin 2005; 26:1421–34.

    Article  PubMed  CAS  Google Scholar 

  39. van Sluijters DA, Dubbelhuis PF, Blommaart EF, Meijer AJ. Amino-acid-dependent signal transduction. Biochem J 2000; 351(Pt 3):545–50.

    Article  PubMed  Google Scholar 

  40. Codogno P, Meijer AJ. Autophagy and signaling: Their role in cell survival and cell death. Cell Death Differ 2005; 12(Supp. 12):1509–18.

    Article  PubMed  CAS  Google Scholar 

  41. Kamada Y, Funakoshi T, Shintani T, Nagano K, Ohsumi M, Ohsumi Y. Tor-mediated induction of autophagy via an Apgl protein kinase complex. J Cell Biol 2000; 150:150713.

    Article  Google Scholar 

  42. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001; 98:9666–70.

    Article  PubMed  CAS  Google Scholar 

  43. Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and maximal activation of ST A T3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 2000; 10:47–50.

    Article  PubMed  CAS  Google Scholar 

  44. Kuo ML, Chuang SE, Lin MT, Yang SY. The involvement of PI 3-KJAkt-dependent upregulation of Mc1-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene 2001; 20:677–85.

    Article  PubMed  CAS  Google Scholar 

  45. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-l/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005; 4:1533–40.

    Article  PubMed  CAS  Google Scholar 

  46. Raje N, Kumar S, Hideshima T, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004; 104:4188–93.

    Article  PubMed  CAS  Google Scholar 

  47. Zangari M, Cavallo F, Tricot G. Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma. Curr Pharm Biotechnol 2006; 7:449–53.

    Article  PubMed  CAS  Google Scholar 

  48. Frost P, Moatomed F, Hoang B, et al. In vivo anti-tumor effects of the mTOR inhibitor, CCI-779, against human multiple myeloma cells in a xenograft model. Blood 2004; 104:4181–4187.

    Article  PubMed  CAS  Google Scholar 

  49. Stromberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004; 103:3138–47.

    Article  PubMed  Google Scholar 

  50. Yan H, Frost P, Shi Y, et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma Cells to dexamethasone-induced apoptosis. Cancer Res 2006; 66:2305–2313.

    Article  PubMed  CAS  Google Scholar 

  51. Frost P, Shi Y, Hoang B, Lichtenstein A. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 2007; 26:2255–2262.

    Article  PubMed  CAS  Google Scholar 

  52. Ikezoe T, Nishioka C, Tasaka T, et al. The antitumor effects of sunitinib (formerly SU 11248) against a variety of human hematologic malignancies: Enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006; 5:2522–30.

    Article  PubMed  CAS  Google Scholar 

  53. Francis LK, Alsayed Y, Leleu X, et al. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 2006; 12:6826–35.

    Article  PubMed  CAS  Google Scholar 

  54. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500–8.

    Article  PubMed  Google Scholar 

  55. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI779) for relapsed mantle cell lymphoma. J Clin Onco1 2005; 23:5347–56.

    Article  CAS  Google Scholar 

  56. Bertoni F, Zucca E, Cotter FE. Molecular basis of mantle cell lymphoma. Br J Haematol 2004; 124:130–40.

    Article  PubMed  CAS  Google Scholar 

  57. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007; 21:333–9.

    Article  PubMed  CAS  Google Scholar 

  58. Farag S, Zhang S, Miller M, et al. Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple Myeloma: Preliminary results. Proc Amer Soc Clin Oncol 2006; 24(18s):450.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, UCLA, The Jonsson Comprehensive Cancer Center and Department of Hematology-Oncology, VA Medical Center, Los Angeles, CA, USA

    Patrick Frost & Alan Lichtenstein

Authors
  1. Patrick Frost
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Lichtenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Winship Cancer Institute, Emory University, B3307 Clifton Road, Atlanta, GA, 30322, USA

    Sagar Lonial MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Frost, P., Lichtenstein, A. (2008). The Mammalian Target of Rapamycin and Multiple Myeloma. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-564-0_21

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-82-4

  • Online ISBN: 978-1-59745-564-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation